Navigation Links
Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
Date:12/6/2010

ORLANDO, Fla., Dec. 6, 2010 /PRNewswire-USNewswire/ -- Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.

The patient's Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not suffered any spontaneous joint bleeds or needed prophylactic treatment.

Study data was presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) by Amit Nathwani, M.D., Ph.D., UCL Department of Hematology, and National Health Service Blood and Transplant, UK, the study's first author. Andrew Davidoff, M.D., chair of the St. Jude Department of Surgery, is the senior author.

Work on the vector began more than 10 years ago in the St. Jude laboratory of Arthur Nienhuis, M.D., member of the Department of Hematology and a study co-author. The collaboration continued after Nathwani returned to London.

The trial vector was made by packaging a codon-optimized version of the Factor IX gene into a member of the adeno-associated virus (AAV) family known as AAV8. AAV8 was picked because the incidence of natural infection with AAV8 is low and, like other AAVs, targe
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. LSU’s Jayne Garno receives early career award from President
2. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
3. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
4. Osteotech Announces Early Termination of HSR Waiting Period
5. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
6. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
7. Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer
8. West Michigan Launches $10 Million Early Stage Venture Fund to Support Life Science & Technology
9. New Study Demonstrates Clinical Validity of EarlyCDT-Lung™
10. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
11. New test takes guesswork out of diagnosing early stage Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... program draws on diverse group to advise on complex infertility ... ... Science,Center of the Bay Area (RSC) is launching an innovative advisory group,designed ... rare development in private medical groups in the,United States. RSC,s ethics ...
... ISELIN, N.J., Nov. 7 SyntheMed, Inc. (OTC,Bulletin ... development,and commercialization of anti-adhesion, tissue repair and drug ... universal shelf registration,statement with the Securities and Exchange ... will allow SyntheMed to sell, from time to,time, ...
... Nov. 7 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: ... Conference Call, ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the ...
Cached Biology Technology:California IVF Experts Tap Ethics Committee for Guidance 2SyntheMed Files Universal Shelf Registration 2Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2
(Date:8/20/2014)... persist in a cold, dark world. A UT microbiology ... waters and sediments from a shallow lake deep beneath ... supports microbial ecosystems. , The National Science Foundation-funded ... for life in other extreme environments, both on Earth ... in the current edition of the science journal ...
(Date:8/20/2014)... this image of the Para and Mato Grosso states ... intentionally set in order to deforest the land. Deforestation ... trees where the land is thereafter converted to a ... to farms, ranches, or urban use. The herringbone-patterned tan ... Rainforest in the middle of the image are evidence ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Singapore, September 3, 2010 Novartis announced today ... (NITD), in collaboration with researchers from the Genomics Institute ... and Public Health Institute and The Scripps Research Institute ... a next generation treatment for drug resistant malaria. Major ...
... the extreme Texas summer heat? Try being an ovulating ... dairy cows suffer from damage to their ovarian follicles. ... also be damaged, said Dr. Todd Bilby, Texas AgriLife ... other studies have shown the eggs she ovulates for ...
... pharmaceutical breakthroughs require 21st-century drug discovery tools, such ... high-throughput screening of effective, new compounds. That,s the ... be held Sept. 11 on "Twenty-first Century Bioscience: ... feature a variety of cutting-edge advances in the ...
Cached Biology News:Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3Test-tube calf embryos more likely to survive Texas summers 2Test-tube calf embryos more likely to survive Texas summers 3University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3
Syd-2 (cL-19)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: